Materialise (Nasdaq: MTLS) reported its third-quarter 2025 outcomes, remaining worthwhile with constructive money movement regardless of weaker efficiency in its manufacturing division. For the third time this 12 months, the corporate’s Medical section led outcomes, setting a brand new quarterly income file and serving to offset slower industrial demand. Up to now, 2025 has been a 12 months outlined by regular medical progress, pointing to Materialise’s energy in 3D printed healthcare options and demand for its software program and patient-specific units.
Materialise Mimics Movement case administration. Picture courtesy of Materialise.
Complete income for the quarter reached €66.3 million ($77.3 million), down 3.5% from the identical interval in 2024. Whereas total gross sales declined, Materialise nonetheless posted a constructive web revenue of €1.8 million ($2 million), or three cents per share, and saved gross margins steady at 56.8%. The corporate continues to show strong price management and environment friendly operations throughout a difficult 12 months for the 3D printing trade as a complete.
CEO Brigitte de Vet-Veithen stated she was happy with the corporate’s continued resilience: “Our Materialise Medical section posted a quarterly income file, rising by greater than 10% in comparison with the identical interval in 2024, whereas macro-economic headwinds continued to influence our consolidated income, and, specifically, our Materialise Manufacturing section. We additional applied focused price management measures designed to guard our operational profitability with out compromising on our continued R&D investments to drive future progress.”
Brigitte de Vet-Veithen from Materialise speaks at AMS 2025. Picture courtesy of 3DPrint.com
Materialise’s Medical section had the perfect outcomes. It grew 10.3% 12 months over 12 months to €33.3 million ($38.8 million), setting a brand new file. This division, which incorporates customized implants, surgical planning, and medical software program, now represents half of Materialise’s complete income. Adjusted EBITDA (earnings earlier than curiosity, taxes, depreciation, and amortization) rose to €10.2 million ($11.9 million), displaying continued profitability at the same time as the corporate expanded R&D funding on this space.
In the meantime, the Software program section, which offers design and manufacturing instruments used throughout the additive trade, reported €10.3 million ($12 million) in income, down 7.4% from final 12 months. Nevertheless, the most important slowdown got here from Materialise Manufacturing, the place income dropped 17.1% to €22.7 million ($26.5 million). The division posted a lack of €800,000 (≈$932,000), in comparison with a small revenue a 12 months earlier. The corporate cited continued macroeconomic pressures and a slower restoration in industrial demand, particularly in Europe, the place many consumers have delayed capital spending.
In truth, if we take a look at current knowledge from the European Central Financial institution and the European Metal Affiliation, they’re amongst many that time to the identical pattern, with “weak manufacturing circumstances” and “subdued funding exercise” throughout the area within the third quarter of 2025. And banks even cited “world uncertainty and commerce tensions” as a dampening issue.
Materialise creates liver digital twins. Picture courtesy of Materialise.
Though revenue was decrease, the corporate ended the quarter with additional cash, a very good signal for liquidity. On the finish of September, Materialise held €132 million ($153.8 million) in money and money equivalents, up from €102 million ($118.9 million) on the finish of 2024. Its web money place rose to €67.7 million ($78.9 million), a €6.7 million ($7.8 million) enhance since December, supported by the robust working money movement of €10.4 million ($12 million).
Gross revenue got here in at €37.7 million ($43.9 million), solely barely beneath final 12 months, pointing to steady price administration. R&D spending rose 4.2%, primarily pushed by new medical applications, whereas total working bills elevated solely 0.5%.
Certainly, Materialise continues to speculate closely in R&D, particularly inside its medical and software program platforms. These investments embrace creating superior surgical planning instruments, bettering simulation software program, and increasing automation in digital manufacturing workflows.
The corporate continues to give attention to data-driven 3D printing. Whereas manufacturing stays weak, Materialise expects its ongoing investments to assist progress as soon as markets stabilize.
De Vet-Veithen identified, “As we strategy the tip of 2025, geopolitical volatility and macro-economic uncertainty proceed to influence the enterprise setting through which we function. We stay assured that our enterprise is strong and resilient, and that Materialise is strongly positioned to seize progress alternatives as soon as market circumstances enhance.”
Materialise CEO Brigitte de Vet-Veithen at Additive Manufacturing Methods 2024. Picture courtesy of 3DPrint.com.
Materialise reaffirmed its full-year steering, anticipating complete income between €265 million ($308.8 million) and €280 million ($326 million) and adjusted EBIT between €6 million ($7 million) and €10 million ($11.7 million). The forecast suggests the corporate expects earnings to stay steady by way of the tip of the 12 months, supported by regular medical demand and price management.
Subscribe to Our E-mail E-newsletter
Keep up-to-date on all the most recent information from the 3D printing trade and obtain data and provides from third celebration distributors.
Add your 3D Fashions and get them printed rapidly and effectively.
